Drug Trial Radar · NCT04867551
A Clinical Study of KDT-3594 in Japanese Patients With Early Parkinson's Disease
Last checked: Nov 20, 2026Latest source record: May 11, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
7
Actual
Start
May 15, 2021
Primary completion
Sep 6, 2021
Study completion Sep 6, 2021
Sponsor
- Lead sponsor
- Kissei Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 30, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 20 years, up to 79 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Objective of this study is to investigate the safety, pharmacokinetics and efficacy of KDT-3594 in patients with early Parkinson's disease without a concomitant medication of L-dopa.
Conditions
- Parkinson Disease
Interventions
KDT-3594Drug
oral administration, dose titration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurrence of adverse eventsTime frame: 8 weeks
- Plasma concentrations of KDT-3594 and its metabolitesTime frame: 8 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Research Site
Multiple Locations, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.